Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 12 2021
Historique:
received: 22 06 2021
accepted: 08 11 2021
entrez: 7 12 2021
pubmed: 8 12 2021
medline: 28 1 2022
Statut: epublish

Résumé

Genomic instability (GI) influences treatment efficacy and resistance, and an accurate measure of it is lacking. Current measures of GI are based on counts of specific structural variation (SV) and mutational signatures. Here, we present a holistic approach to measuring GI based on the quantification of the steady-state equilibrium between DNA damage and repair as assessed by the residual breakpoints (BP) remaining after repair, irrespective of SV type. We use the notion of Hscore, a BP "hotspotness" magnitude scale, to measure the propensity of genomic structural or functional DNA elements to break more than expected by chance. We then derived new measures of transcription- and replication-associated GI that we call iTRAC (transcription-associated chromosomal instability index) and iRACIN (replication-associated chromosomal instability index). We show that iTRAC and iRACIN are predictive of metastatic relapse in Leiomyosarcoma (LMS) and that they may be combined to form a new classifier called MAGIC (mixed transcription- and replication-associated genomic instability classifier). MAGIC outperforms the gold standards FNCLCC and CINSARC in stratifying metastatic risk in LMS. Furthermore, iTRAC stratifies chemotherapeutic response in LMS. We finally show that this approach is applicable to other cancers.

Identifiants

pubmed: 34873180
doi: 10.1038/s41598-021-02787-x
pii: 10.1038/s41598-021-02787-x
pmc: PMC8648741
doi:

Substances chimiques

Antineoplastic Agents 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

23429

Informations de copyright

© 2021. The Author(s).

Références

Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability—An evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228 (2010).
pubmed: 20177397 doi: 10.1038/nrm2858
Tubbs, A. & Nussenzweig, A. Endogenous DNA damage as a source of genomic instability in cancer. Cell 168, 644–656 (2017).
pubmed: 28187286 pmcid: 6591730 doi: 10.1016/j.cell.2017.01.002
Gaillard, H., García-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276–289 (2015).
pubmed: 25907220 doi: 10.1038/nrc3916
Macheret, M. & Halazonetis, T. D. DNA Replication stress as a hallmark of cancer. Annu. Rev. Pathol. Mech. Dis. 10, 425–448 (2015).
doi: 10.1146/annurev-pathol-012414-040424
Técher, H., Koundrioukoff, S., Nicolas, A. & Debatisse, M. The impact of replication stress on replication dynamics and DNA damage in vertebrate cells. Nat. Rev. Genet. 18, 535–550 (2017).
pubmed: 28714480 doi: 10.1038/nrg.2017.46
Debatisse, M., Le Tallec, B., Letessier, A., Dutrillaux, B. & Brison, O. Common fragile sites: Mechanisms of instability revisited. Trends Genet. 28, 22–32 (2012).
pubmed: 22094264 doi: 10.1016/j.tig.2011.10.003
Le Tallec, B. et al. Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Rep. 4, 420–428 (2013).
pubmed: 23911288 doi: 10.1016/j.celrep.2013.07.003
Blin, M. et al. Transcription-dependent regulation of replication dynamics modulates genome stability. Nat. Struct. Mol. Biol. 26, 58–66 (2019).
pubmed: 30598553 doi: 10.1038/s41594-018-0170-1
Aguilera, A. The connection between transcription and genomic instability. EMBO J. 21, 195–201 (2002).
pubmed: 11823412 pmcid: 125829 doi: 10.1093/emboj/21.3.195
Jinks-Robertson, S. & Bhagwat, A. S. Transcription-associated mutagenesis. Annu. Rev. Genet. 48, 341–359 (2014).
pubmed: 25251854 doi: 10.1146/annurev-genet-120213-092015
Kim, N. & Jinks-Robertson, S. Transcription as a source of genome instability. Nat. Rev. Genet. 13, 204–214 (2012).
pubmed: 22330764 pmcid: 3376450 doi: 10.1038/nrg3152
Gaillard, H., Herrera-Moyano, E. & Aguilera, A. Transcription-associated genome instability. Chem. Rev. 113, 8638–8661 (2013).
pubmed: 23597121 doi: 10.1021/cr400017y
Marnef, A., Cohen, S. & Legube, G. Transcription-coupled DNA double-strand break repair: Active genes need special care. J. Mol. Biol. 429, 1277–1288 (2017).
pubmed: 28363678 doi: 10.1016/j.jmb.2017.03.024
Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 44, 966–977 (2011).
pubmed: 22195969 doi: 10.1016/j.molcel.2011.10.013
Wilson, T. E. et al. Large transcription units unify copy number variants and common fragile sites arising under replication stress. Genome Res. 25, 189–200 (2015).
pubmed: 25373142 pmcid: 4315293 doi: 10.1101/gr.177121.114
Pentzold, C. et al. FANCD2 binding identifies conserved fragile sites at large transcribed genes in avian cells. Nucleic Acids Res. 46, 1280–1294 (2018).
pubmed: 29253234 doi: 10.1093/nar/gkx1260
Madireddy, A. et al. FANCD2 facilitates replication through common fragile sites. Mol. Cell 64, 388–404 (2016).
pubmed: 27768874 pmcid: 5683400 doi: 10.1016/j.molcel.2016.09.017
Gaillard, H. & Aguilera, A. Transcription as a threat to genome integrity. Annu. Rev. Biochem. 85, 291–317 (2016).
pubmed: 27023844 doi: 10.1146/annurev-biochem-060815-014908
Azvolinsky, A., Giresi, P. G., Lieb, J. D. & Zakian, V. A. Highly transcribed RNA polymerase II genes are impediments to replication fork progression in Saccharomyces cerevisiae. Mol. Cell 34, 722–734 (2009).
pubmed: 19560424 pmcid: 2728070 doi: 10.1016/j.molcel.2009.05.022
French, S. Consequences of replication fork movement through transcription units in vivo. Science 258, 1362–1365 (1992).
pubmed: 1455232 doi: 10.1126/science.1455232
Deshpande, A. M. & Newlon, C. S. DNA replication fork pause sites dependent on transcription. Science 272, 1030–1033 (1996).
pubmed: 8638128 doi: 10.1126/science.272.5264.1030
Cahill, D. P., Kinzler, K. W., Vogelstein, B. & Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Genet. 15, M57–M60 (1999).
doi: 10.1016/S0168-9525(99)01874-0
Bakhoum, S. F. et al. Numerical chromosomal instability mediates susceptibility to radiation treatment. Nat. Commun. 6, 5990 (2015).
pubmed: 25606712 doi: 10.1038/ncomms6990
Lee, H.-S. et al. Effects of anticancer drugs on chromosome instability and new clinical implications for tumor-suppressing therapies. Can. Res. 76, 902–911 (2016).
doi: 10.1158/0008-5472.CAN-15-1617
Kim, J.-H. et al. Development of a novel HAC-based “gain of signal” quantitative assay for measuring chromosome instability (CIN) in cancer cells. Oncotarget 7, 14841–14856 (2016).
pubmed: 26943579 pmcid: 4924756 doi: 10.18632/oncotarget.7854
Janssen, A., Kops, G. J. P. L. & Medema, R. H. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. PNAS 106, 19108–19113 (2009).
pubmed: 19855003 pmcid: 2776415 doi: 10.1073/pnas.0904343106
Zasadil, L. M. et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci. Transl. Med. 6, 229 (2014).
doi: 10.1126/scitranslmed.3007965
Birkbak, N. J. et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Can. Res. 71, 3447–3452 (2011).
doi: 10.1158/0008-5472.CAN-10-3667
Roylance, R. et al. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol. Biomark. Prev. 20, 2183–2194 (2011).
doi: 10.1158/1055-9965.EPI-11-0343
Blay, J.-Y. et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann. Oncol. 28, 2852–2859 (2017).
pubmed: 29117335 pmcid: 5834019 doi: 10.1093/annonc/mdx484
Chibon, F. et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat. Med. 16, 781–787 (2010).
pubmed: 20581836 doi: 10.1038/nm.2174
Derré, J. et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: An analysis of a series of 27 leiomyosarcomas. Lab. Investig. 81, 211–215 (2001).
pubmed: 11232643 doi: 10.1038/labinvest.3780229
Pérot, G. et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am. J. Pathol. 177, 2080–2090 (2010).
pubmed: 20884963 pmcid: 2947301 doi: 10.2353/ajpath.2010.100104
Coindre, J. M. et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91, 1914–1926 (2001).
pubmed: 11346874 doi: 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3
Spencer, D. H. et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J. Mol. Diagn. 15, 623–633 (2013).
pubmed: 23810758 pmcid: 4912568 doi: 10.1016/j.jmoldx.2013.05.004
Shabani Azim, F., Houri, H., Ghalavand, Z. & Nikmanesh, B. Next generation sequencing in clinical oncology: Applications, challenges and promises: A review article. Iran. J. Public Health 47, 1453–1457 (2018).
pubmed: 30524974 pmcid: 6277731
Andersson, C., Fagman, H., Hansson, M. & Enlund, F. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing. Cancer Genet. 209, 154–160 (2016).
pubmed: 26987750 doi: 10.1016/j.cancergen.2016.02.004
Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, 8399 (2017).
doi: 10.1126/science.aaf8399
Limpert, E., Stahel, W. A. & Abbt, M. Log-normal distributions across the sciences: Keys and clues. Bioscience 51, 341 (2001).
doi: 10.1641/0006-3568(2001)051[0341:LNDATS]2.0.CO;2
Wang, G. & Vasquez, K. M. Impact of alternative DNA structures on DNA damage, DNA repair, and genetic instability. DNA Repair 19, 143–151 (2014).
pubmed: 24767258 pmcid: 4216180 doi: 10.1016/j.dnarep.2014.03.017
Nguyen, M., Ekstrom, A., Li, X. & Yin, Y. HGT-Finder: A new tool for horizontal gene transfer finding and application to Aspergillus genomes. Toxins 7, 4035–4053 (2015).
pubmed: 26473921 pmcid: 4626719 doi: 10.3390/toxins7104035
Mourad, R., Ginalski, K., Legube, G. & Cuvier, O. Predicting double-strand DNA breaks using epigenome marks or DNA at kilobase resolution. Genome Biol. 19, 34 (2018).
pubmed: 29544533 pmcid: 5856001 doi: 10.1186/s13059-018-1411-7
Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
pmcid: 4530010 doi: 10.1038/nature14248
Chèneby, J., Gheorghe, M., Artufel, M., Mathelier, A. & Ballester, B. ReMap 2018: An updated atlas of regulatory regions from an integrative analysis of DNA-binding ChIP-seq experiments. Nucleic Acids Res. 46, D267–D275 (2018).
pubmed: 29126285 doi: 10.1093/nar/gkx1092
Ahmad, S. S., Ahmed, K. & Venkitaraman, A. R. Science in focus: Genomic instability and its implications for clinical cancer Care. Clin. Oncol. 30, 751–755 (2018).
doi: 10.1016/j.clon.2018.09.001
Guillou, L. et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. JCO 15, 350–362 (1997).
doi: 10.1200/JCO.1997.15.1.350
Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105–113 (2016).
pubmed: 26618723 doi: 10.1038/nm.3984
Zhang, S., Yuan, Y. & Hao, D. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS ONE 9, e113169 (2014).
pubmed: 25437005 pmcid: 4249855 doi: 10.1371/journal.pone.0113169
Birkbak, N. J. et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2, 366–375 (2012).
pubmed: 22576213 pmcid: 3806629 doi: 10.1158/2159-8290.CD-11-0206
Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776–1782 (2012).
pubmed: 23047548 pmcid: 3493866 doi: 10.1038/bjc.2012.451
Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Can. Res. 72, 5454–5462 (2012).
doi: 10.1158/0008-5472.CAN-12-1470
Stefansson, O. A. et al. Genomic profiling of breast tumours in relation to BRCAabnormalities and phenotypes. Breast Cancer Res. 11, R47 (2009).
pubmed: 19589159 pmcid: 2750106 doi: 10.1186/bcr2334
Baumbusch, L. O. et al. High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS ONE 8, e54356 (2013).
pubmed: 23372714 pmcid: 3553118 doi: 10.1371/journal.pone.0054356
Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).
pubmed: 27717299 doi: 10.1056/NEJMoa1611310
Morgan, G., Ward, R. & Barton, M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin. Oncol. 16, 549–560 (2004).
doi: 10.1016/j.clon.2004.06.007
Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
pubmed: 30345884 doi: 10.1056/NEJMoa1810858
Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018).
pubmed: 30110579 doi: 10.1056/NEJMoa1802905
Chudasama, P. et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat. Commun. 9, 144 (2018).
pubmed: 29321523 pmcid: 5762758 doi: 10.1038/s41467-017-02602-0
Fletcher, C. D. M. (ed.) Pathology and Genetics of Tumours of Soft Tissue and Bone (IARC Press, 2002).
Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159 (1987).
pubmed: 2440339 doi: 10.1016/0003-2697(87)90021-2
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
Schneider, V. A. et al. Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. Genome Res. 27, 849–864 (2017).
pubmed: 28396521 pmcid: 5411779 doi: 10.1101/gr.213611.116
Li, H. et al. The sequence alignment/Map FORMAT and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
pubmed: 19261174 pmcid: 2690996 doi: 10.1186/gb-2009-10-3-r25
Kent, W. J. BLAT–the BLAST-like alignment tool. Genome Res. 12, 656–664 (2002).
pubmed: 11932250 pmcid: 187518
Cer, R. Z. et al. Non-B DB v2.0: A database of predicted non-B DNA-forming motifs and its associated tools. Nucleic Acids Res. 41, D94–D100 (2012).
pubmed: 23125372 pmcid: 3531222 doi: 10.1093/nar/gks955
Jenjaroenpun, P., Wongsurawat, T., Yenamandra, S. P. & Kuznetsov, V. A. QmRLFS-finder: A model, web server and stand-alone tool for prediction and analysis of R-loop forming sequences. Nucleic Acids Res. 43, W527–W534 (2015).
pubmed: 25883153 pmcid: 4489302 doi: 10.1093/nar/gkv344
Kuhn, R. M., Haussler, D. & Kent, W. J. The UCSC genome browser and associated tools. Brief Bioinform. 14, 144–161 (2013).
pubmed: 22908213 doi: 10.1093/bib/bbs038
Zhou, W. et al. Increased genome instability in human DNA segments with self-chains: Homology-induced structural variations via replicative mechanisms. Hum. Mol. Genet. 22, 2642–2651 (2013).
pubmed: 23474816 pmcid: 3674805 doi: 10.1093/hmg/ddt113

Auteurs

Ataaillah Benhaddou (A)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.

Laetitia Gaston (L)

Department of Medical Genetics, CHU de Bordeaux, 33000, Bordeaux, France.

Gaëlle Pérot (G)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.
Centre Hospitalier Universitaire (CHU) de Toulouse, IUCT-Oncopole, 31000, Toulouse, France.

Nelly Desplat (N)

INSERM UMR1218, ACTION, Institut Bergonié, 33000, Bordeaux, France.

Laura Leroy (L)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.
Department of Pathology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

Sophie Le Guellec (S)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.
Department of Pathology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

Mohamed Ben Haddou (M)

Mentis Consulting, 1000, Brussels, Belgique.

Philippe Rochaix (P)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.
Department of Pathology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

Thibaud Valentin (T)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.
Department of Oncology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

Gwenaël Ferron (G)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.
Department of Surgical Oncology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

Christine Chevreau (C)

Department of Oncology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

Binh Bui (B)

Department of Oncology, Institut Bergonié, 33000, Bordeaux, France.

Eberhard Stoeckle (E)

Department of Surgery, Institut Bergonié, 33000, Bordeaux, France.

Axel Le Cesne (A)

Department of Oncology, Institut Gustave Roussy, 94800, Villejuif, France.

Sophie Piperno-Neumann (S)

Department of Medical Oncology, Institut Curie, 75005, Paris, France.

Françoise Collin (F)

Department of Pathology, Centre Georges-François Leclerc, 21000, Dijon, France.

Nelly Firmin (N)

Department of Oncology, Institut Régional du Cancer de Montpellier, 34000, Montpellier, France.

Gonzague De Pinieux (G)

Department of Pathology, Hôpital Universitaire Trousseau, 37170, Tours, France.

Jean-Michel Coindre (JM)

Department of Pathology, Institut Bergonié, 33000, Bordeaux, France.

Jean-Yves Blay (JY)

Department of Medical Oncology, Centre Léon Bérard, 69000, Lyon, France.
Centre Léon Bérard, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, 69000, Lyon, France.

Frédéric Chibon (F)

OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France. Frederic.chibon@inserm.fr.
Department of Pathology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France. Frederic.chibon@inserm.fr.
Cancer Research Center in Toulouse (CRCT), 2 Avenue Hubert Curien, 31037, Toulouse, France. Frederic.chibon@inserm.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH